Online:
Visits:
Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

$IGC Coverage – Unique Cannabis-Pharma Companies Trailblazing the Medical Cannabis Industry

Thursday, March 16, 2017 6:11
% of readers think this story is Fact. Add your two cents.

(Before It's News)

FinancialNewsMedia.com News Alert: NEW YORK, (http://www.financialnewsmedia.com News Alert) – NetworkNewsWire Editorial Coverage: The cannabis industry has swiftly turned into a multi-billion dollar opportunity. In the United States, this market’s massive growth potential is being recognized as new states legalize marijuana for medical or recreational use. Industry experts forecast the U.S. cannabis market rounding $7 billion in 2016, while the annual sale of state-legal cannabis products is forecast to exceed $20 billion by 2020. Within this flourishing market, cannabis-pharma companies like India Globalization Capital (NYSE: IGC) IGC Profile – https://www.networknewswire.com/clients/india-globalization-capital-inc-igc/?symbol=igc, Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), OWC Pharmaceutical Research Corp. (OTC:OWCP), Insys Therapeutics, Inc. (NASDAQ: INSY) and GW Pharmaceuticals plc (NASDAQ: GWPH) are carving lanes of unprecedented opportunities in the medical field.

Bethesda, Maryland-based India Globalization Capital (NYSE: IGC) (IGC Profile) is advancing the development of cannabis-based therapies targeting large market conditions and illnesses. IGC is on a mission to treat chronic and terminal neurological and oncological diagnoses and other life altering conditions utilizing an exciting and specialized IP platform that formulates and tests combination therapies. With this special focus in mind, IGC has amassed a portfolio of patent filings covering the indications of pain, medical refractory epilepsy and cachexia (cancer-induced anorexia) using cannabinoids. As we will further discuss later, IGC has established an approach that significantly differentiates the company from its cannabis-pharma peers.

Like IGC, Zynerba Pharmaceuticals (NASDAQ: ZYNE) is dedicated to the development of innovative cannabinoid treatments that target seizures and pain. Unlike IGC and Cannabics, this clinical-stage, specialty pharmaceutical company is concentrating on developing transdermal synthetic cannabinoid treatments. On March 13, 2017, the company announced that it had completed enrolling patients for Phase 2 of its STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial evaluating ZYN002 cannabidiol (CBD) gel in adult epilepsy…



Source: http://www.financialnewsmedia.com/stock-investing-business-investing-news/featured-news.php?id=993

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories
 

Featured

 

Top Global

 

Top Alternative

 

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.